# This Will be a Randomized Comparison of the Proteomic Effects of Vicadrostat/Empagliflozin Versus Empagliflozin and Versus Empagliflozin/Spironolactone in Heart Failure Patients With Preserved Ejection Fraction

Study · id `cardio:ct-nct07857772` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07857772](<https://clinicaltrials.gov/study/NCT07857772>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07857772

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 200 participants.

## Technical summary

Registry record NCT07857772. Randomized; quadruple masking; primary purpose treatment. Start 2027-03 (anticipated); primary completion 2028-05 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 200 participants (planned count; ClinicalTrials.gov record NCT07857772, source copy `cardio:ctgov-nct07857772-2026-10-05`, retrieved 2026-10-26)
- Planned start: 2027-03 (anticipated) (ClinicalTrials.gov record NCT07857772, source copy `cardio:ctgov-nct07857772-2026-10-05`, retrieved 2026-10-26)
- Primary completion: 2028-05 (anticipated) (ClinicalTrials.gov record NCT07857772, source copy `cardio:ctgov-nct07857772-2026-10-05`, retrieved 2026-10-26)
- Completion: 2028-09 (anticipated) (ClinicalTrials.gov record NCT07857772, source copy `cardio:ctgov-nct07857772-2026-10-05`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07857772-2026-10-05`, retrieved 2026-10-26)

## The registry's words

- Brief title: This Will be a Randomized Comparison of the Proteomic Effects of Vicadrostat/Empagliflozin Versus Empagliflozin and Versus Empagliflozin/Spironolactone in Heart Failure Patients With Preserved Ejection Fraction
- Acronym: SPECTRA-HFpEF
- Condition: Heart Failure With Preserved Ejection Fraction (HFPEF)
- Intervention (Drug): empa plus vica
- Intervention (Drug): Comparator: empa 10 plus spironolactone
- Lead sponsor: Baim Institute for Clinical Research
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry condition term reads as this condition, and the trial is coded with its broader condition: Heart failure with mildly reduced or preserved ejection fraction (`cardio:hfpef`)
- Registry lists this organization as the lead sponsor: Baim Institute for Clinical Research (`cardio:org-baim-institute-for-clinical-research`)

## Provenance

Content hash: f58aa3fc57a28d1185af7237c95d7bb1a809dad228eaeb7516eb93a462ac4166
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
